Wide Ranks

MGNX

MacroGenics, Inc.

3.64

Top Statistics
Market Cap 228 M Forward PE -1.46 Revenue Growth 964.80 %
Current Ratio 3.75 Trailing PE 0.0000 Earnings Growth 220.50 %
Profit Margins -69.07 % Peg Ratio Dividend Yield 0.00 %
Enterprice / EBITA -0.6240 Enterprise / Revenue 0.4400 Price To Sales Trailing12 Months 1.62
Profitability
Profit Margins -69.07 % Operating Margins 48.95 %
Balance Sheet
Total Cash 200 M Total Cash Per Share 3.19 Total Debt 34 M
Total Debt To Equity 28.40 Current Ratio 3.75 Book Value Per Share 1.91
All Measures
Short Ratio 735.00 % Message Board Id finmb_600911 Fax 301 251 5321
Shares Short Prior Month 5 M Return On Equity -0.6217 City Rockville
Uuid 322da638-92af-3f5e-9fb0-7915224804a7 Previous Close 3.40 First Trade Date Epoch Utc 1 B
Book Value 1.91 Beta 2.08 Total Debt 34 M
Volume 566404 Price To Book 1.90 Fifty Two Week Low 2.95
Total Cash Per Share 3.19 Total Revenue 141 M Shares Short Previous Month Date 1 B
Target Median Price 7.00 Audit Risk 3 Max Age 86400
Recommendation Mean 2.36 Sand P52 Week Change 0.3133 Operating Margins 48.95 %
Target Mean Price 7.38 Net Income To Common -97617000 Short Percent Of Float 0.0996
Implied Shares Outstanding 62 M Trailing Peg Ratio None Last Fiscal Year End 1 B
Average Daily Volume10 Day 532940 Average Volume10days 532940 Total Cash 200 M
Next Fiscal Year End 1 B Revenue Per Share 2.26 Held Percent Insiders 0.0264
Ebitda Margins -70.55 % Trailing PE 0.0000 Date Short Interest 1 B
Most Recent Quarter 1 B Share Holder Rights Risk 7 Regular Market Previous Close 3.40
Target Low Price 4.00 Gmt Off Set Milliseconds -18000000 Fifty Day Average 3.65
Open 3.45 Free Cashflow -21178250 State MD
Dividend Yield 0.00 % Return On Assets -0.2215 Time Zone Short Name EST
Board Risk 3 Trailing Eps -1.57 Day Low 3.43
Address1 9704 Medical Center Drive Shares Outstanding 62 M Compensation Risk 6
Price Hint 4 Target High Price 14.00 Website https://www.macrogenics.com
52 Week Change -0.5566 Average Volume 651103 Earnings Quarterly Growth 220.80 %
Forward Eps -2.41 Recommendation Key buy Compensation As Of Epoch Date 1 B
Quick Ratio 352.60 % Is_sp_500 False Regular Market Day High 3.68
Profit Margins -69.07 % Debt To Equity 28.40 Fifty Two Week High 21.88
Day High 3.68 Shares Short 5 M Regular Market Open 3.45
Industry Key biotechnology Earnings Growth 220.50 % Enterprise To Revenue 0.4400
Revenue Growth 964.80 % Shares Percent Shares Out 0.0812 Operating Cashflow -58003000
Currency USD Time Zone Full Name America/New_York Market Cap 228 M
Is_nasdaq_100 False Zip 20850 Quote Type EQUITY
Industry Biotechnology Long Name MacroGenics, Inc. Overall Risk 5
Regular Market Day Low 3.43 Held Percent Institutions 0.9372 Current Price 3.64
Enterprise To Ebitda -0.6240 Financial Currency USD Current Ratio 3.75
Gross Margins -36.30 % Industry Disp Biotechnology Number Of Analyst Opinions 8
Country United States Float Shares 51 M Two Hundred Day Average 7.74
Governance Epoch Date 1 B Enterprise Value 62 M Price To Sales Trailing12 Months 1.62
Forward PE -1.46 Regular Market Volume 566404 Ebitda -99708000
Exchange NMS
Go to Yahoo Finance Go to Seeking Alpha 
MacroGenics, Inc., a biopharmaceutical company, develops, manufactures, and commercializes antibody-based therapeutics to treat cancer in the United States.

Its approved product is MARGENZA (margetuximab-cmkb), a human epidermal growth factor receptor 2 (HER2) receptor antagonist indicated, in combination with chemotherapy, for the treatment of adult patients with metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 regimens.

The company's pipeline of immuno-oncology product candidates includes MGC018, an antibody drug conjugate (ADC), which targets solid tumors expressing B7-H3; Enoblituzumab, a monoclonal antibody that targets B7-H3; and MGD024, an investigational bispecific CD123 × CD3 DART molecule to minimize cytokine-release syndrome for patients with hematologic malignancies.

In addition, it develops Lorigerlimab, a monoclonal antibody that targets the immune checkpoints PD-1 and cytotoxic T-lymphocyte-associated protein 4; Tebotelimab, an investigational tetravalent DART molecule for PD-1 and lymphocyte-activation gene 3; Retifanlimab, a humanized monoclonal antibody targeting programmed death receptor-1; and IMGC936, an ADC that targets ADAM9, a cell surface protein over-expressed in various solid tumor types.

Further, the company develops MGD014 and MGD020, a DART molecule to target the envelope protein of human immunodeficiency virus infected cells and CD3 on T cells; Teplizumab for the treatment of type 1 diabetes; and PRV-3279, a CD32B × CD79B DART molecule for the treatment of autoimmune indications.

It has collaborations with Incyte Corporation; Zai Lab Limited; I-Mab Biopharma; and Janssen Biotech, Inc. The company was incorporated in 2000 and is headquartered in Rockville, Maryland.